Ketoprofen

Identification

Name

Ketoprofen

Accession Number

DB01009  (APRD01059, DB05823, DB05335)

Type

Small Molecule

Groups

Approved, Vet approved

Description

Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB01009 (Ketoprofen)

×

Close

Synonyms

• 2-(3-Benzoylphenyl)propionic acid
• 3-Benzoyl-alpha-methylbenzeneacetic acid
• 3-Benzoyl-α-methylbenzeneacetic acid
• 3-Benzoylhydratropic acid
• Ketoprofen
• L'Acide (benzoyl-3-phenyl)-2-propionique
• m-Benzoylhydratropic acid
• Orudis (tn)

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Ketoprofen sodium	5R10M39KS7	57495-14-4	OAPDLBHLMVYMCW-UHFFFAOYSA-M

Product Images

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Ketoprofen	Capsule	50 mg	Oral	Aa Pharma Inc	1989-12-31	Not applicable
Ketoprofen SR	Tablet, extended release	200 mg	Oral	Aa Pharma Inc	1995-12-31	Not applicable
Ketoprofen Suppositories	Suppository	50 mg	Rectal	Pharmel Inc	Not applicable	Not applicable
Ketoprofen Suppositories	Suppository	100 mg	Rectal	Pharmel Inc	1998-06-04	Not applicable
Ketoprofen-E	Tablet, delayed release	100 mg	Oral	Aa Pharma Inc	1989-12-31	Not applicable
Ketoprofen-E	Tablet, delayed release	50 mg	Oral	Aa Pharma Inc	1989-12-31	Not applicable
Ketoprofen-E Ect 100mg	Tablet, delayed release	100 mg	Oral	Pro Doc Limitee	1996-12-31	2009-07-23
Ketoprofen-E Ect 50mg	Tablet, delayed release	50 mg	Oral	Pro Doc Limitee	1995-12-31	2009-07-23
Ketoprofen-SR - Srt 200mg	Tablet, extended release	200 mg	Oral	Pro Doc Limitee	1997-09-18	2009-07-23
Orafen - Sup RT 100mg	Suppository	100 mg	Rectal	Technilab Pharma Inc.	1996-12-31	2004-08-03

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Ketoprofen	Capsule	75 mg/1	Oral	Stat Rx USA	2011-01-18	2018-02-08
Ketoprofen	Capsule	75 mg/1	Oral	Aidarex Pharmaceuticals LLC	1993-01-01	Not applicable
Ketoprofen	Capsule, extended release	200 mg/1	Oral	Physicians Total Care, Inc.	2009-06-23	Not applicable
Ketoprofen	Capsule	50 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1993-01-01	Not applicable
Ketoprofen	Capsule	75 mg/1	Oral	Teva	1993-01-01	Not applicable
Ketoprofen	Capsule	50 mg/1	Oral	A S Medication Solutions	1993-01-01	Not applicable
Ketoprofen	Capsule	75 mg/1	Oral	A S Medication Solutions	1993-01-01	2017-06-20
Ketoprofen	Capsule	75 mg/1	Oral	Nucare Pharmaceuticals, Inc.	1993-01-01	Not applicable
Ketoprofen	Capsule	75 mg/1	Oral	Mylan Pharmaceuticals	1997-01-15	2018-01-23
Ketoprofen	Capsule	75 mg/1	Oral	Rebel Distributors	2010-04-20	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Ketophene	Ketoprofen (33.5 g/33.5g)	Kit		California Pharmaceuticals, Llc	2016-01-01	Not applicable
Vopac - Ketoprofen, Lidocaine Hydrochloride Pac	Ketoprofen	Kit		Sircle Laboratories, Llc	2015-03-01	2017-07-13

International/Other Brands

Actron / Alrheumun (Teofarma) / Capisten (Kissei) / Epatec (Zeria Shinyaku) / Fastum (Menarini) / Menamin (Daiko Seiyaku) / Orudis (Abbott) / Orudis KT (Sanofi) / Orugesic (Sanofi) / Oruvail (Wyeth) / Oscorel (Sanofi) / Profenid (Sanofi) / Toprec (Sanofi)

Categories

• Acids, Carbocyclic
• Analgesics
• Analgesics, Non-Narcotic
• Anti-Inflammatory Agents
• Anti-Inflammatory Agents, Non-Steroidal
• Antiinflammatory and Antirheumatic Products
• Antiinflammatory and Antirheumatic Products, Non-Steroids
• Antirheumatic Agents
• Central Nervous System Agents
• Cyclooxygenase Inhibitors
• Cytochrome P-450 CYP2C8 Inhibitors
• Cytochrome P-450 CYP2C9 Inhibitors
• Cytochrome P-450 CYP2C9 Substrates
• Cytochrome P-450 Enzyme Inhibitors
• Enzyme Inhibitors
• Musculo-Skeletal System
• Nonsteroidal Anti-inflammatory Drug
• Other Nonsteroidal Antiimflammatory Agents
• Peripheral Nervous System Agents
• Phenylpropionates
• Propionates
• Sensory System Agents

UNII

90Y4QC304K

CAS number

22071-15-4

Weight

Average: 254.2806
Monoisotopic: 254.094294314

Chemical Formula

C₁₆H₁₄O₃

InChI Key

DKYWVDODHFEZIM-UHFFFAOYSA-N

InChI

InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)

IUPAC Name

2-(3-benzoylphenyl)propanoic acid

SMILES

CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1

Pharmacology

Indication

For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.

Structured Indications

• Ankylosing Spondylitis (AS)
• Migraines
• Osteoarthritis (OA)
• Pain
• Postpartum pain
• Primary Dysmenorrhoea
• Rheumatoid Arthritis

Pharmacodynamics

Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.

Mechanism of action

The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.

Target	Actions	Organism
UProstaglandin G/H synthase 1	inhibitor	Human
AProstaglandin G/H synthase 2	inhibitor	Human
UC-X-C chemokine receptor type 1	other	Human

Absorption

Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.

Volume of distribution

Not Available

Protein binding

99% bound, primarily to albumin

Metabolism

Rapidly and extensively metabolized in the liver, primarily via conjugation to glucuronic acid. No active metabolites have been identified.

• Ketoprofen
  Ketoprofen glucuronide

Route of elimination

In a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite.

Half life

Conventional capsules: 1.1-4 hours

Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)

Clearance

• Oral-dose cl=6.9 +/- 0.8 L/h [Ketoprofen Immediate-release capsules (4 × 50 mg)]
• Oral-dose cl=6.8 +/- 1.8 L/h [Ketoprofen Extended-release capsules (1 × 200 mg)]
• 0.08 L/kg/h
• 0.7 L/kg/h [alcoholic cirrhosis patients]

Toxicity

LD₅₀=62.4 mg/kg (rat, oral).

Symptoms of overdose include drowsiness, vomiting and abdominal pain.

Side effects are usually mild and mainly involved the GI tract. Most common adverse GI effect is dyspepsia (11% of patients). May cause nausea, diarrhea, abdominal pain, constipation and flatulence in greater than 3% of patients.

Affected organisms

• Humans and other mammals

Pathways

Pathway	Category
Ketoprofen Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(4R)-limonene	The risk or severity of adverse effects can be increased when Ketoprofen is combined with (4R)-limonene.	Investigational
16-Bromoepiandrosterone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with 16-Bromoepiandrosterone.	Investigational
19-norandrostenedione	The risk or severity of adverse effects can be increased when Ketoprofen is combined with 19-norandrostenedione.	Experimental, Illicit
5-androstenedione	The risk or severity of adverse effects can be increased when Ketoprofen is combined with 5-androstenedione.	Experimental, Illicit
Abciximab	Ketoprofen may increase the anticoagulant activities of Abciximab.	Approved
Abiraterone	The metabolism of Ketoprofen can be decreased when combined with Abiraterone.	Approved
Acebutolol	Ketoprofen may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Aceclofenac	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Aceclofenac.	Approved, Investigational
Acemetacin	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Acemetacin.	Approved, Experimental, Investigational
Acenocoumarol	Ketoprofen may increase the anticoagulant activities of Acenocoumarol.	Approved, Investigational
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ketoprofen.	Approved, Vet Approved
Aclarubicin	Ketoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.	Investigational
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Ketoprofen.	Approved
Alclofenac	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alclofenac.	Approved, Withdrawn
Alclometasone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alclometasone.	Approved
Aldosterone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Aldosterone.	Experimental, Investigational
Aldoxorubicin	Ketoprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.	Investigational
Alendronic acid	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alendronic acid.	Approved
Aliskiren	Ketoprofen may decrease the antihypertensive activities of Aliskiren.	Approved, Investigational
Alminoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alminoprofen.	Experimental
Alprenolol	Ketoprofen may decrease the antihypertensive activities of Alprenolol.	Approved, Withdrawn
Alprostadil	The therapeutic efficacy of Alprostadil can be decreased when used in combination with Ketoprofen.	Approved, Investigational
Amcinonide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Amcinonide.	Approved
Amikacin	Ketoprofen may decrease the excretion rate of Amikacin which could result in a higher serum level.	Approved, Investigational, Vet Approved
Amiloride	Ketoprofen may decrease the antihypertensive activities of Amiloride.	Approved
Amiodarone	The metabolism of Ketoprofen can be decreased when combined with Amiodarone.	Approved, Investigational
Amodiaquine	The serum concentration of Amodiaquine can be increased when it is combined with Ketoprofen.	Approved, Investigational
Amrubicin	Ketoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.	Approved, Investigational
Ancrod	Ketoprofen may increase the anticoagulant activities of Ancrod.	Approved, Investigational
Andrographolide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Andrographolide.	Investigational
Androstenedione	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Androstenedione.	Experimental, Illicit
Anecortave	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Anecortave.	Investigational
anecortave acetate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with anecortave acetate.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Anisodamine.	Investigational
Annamycin	Ketoprofen may decrease the excretion rate of Annamycin which could result in a higher serum level.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Antipyrine.	Approved, Investigational
Antithrombin III human	Ketoprofen may increase the anticoagulant activities of Antithrombin III human.	Approved
Apalutamide	The serum concentration of Ketoprofen can be decreased when it is combined with Apalutamide.	Approved, Investigational
Apixaban	Ketoprofen may increase the anticoagulant activities of Apixaban.	Approved
Apocynin	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Apocynin.	Investigational
Apramycin	Ketoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.	Experimental, Vet Approved
Apremilast	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Apremilast.	Approved, Investigational
Aprepitant	The metabolism of Ketoprofen can be increased when combined with Aprepitant.	Approved, Investigational
Arbekacin	Ketoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.	Approved, Investigational
Ardeparin	Ketoprofen may increase the anticoagulant activities of Ardeparin.	Approved, Investigational, Withdrawn
Argatroban	Ketoprofen may increase the anticoagulant activities of Argatroban.	Approved, Investigational
Arotinolol	Ketoprofen may decrease the antihypertensive activities of Arotinolol.	Investigational
Atamestane	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Atamestane.	Investigational
Atenolol	Ketoprofen may decrease the antihypertensive activities of Atenolol.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Azapropazone.	Withdrawn
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Ketoprofen.	Approved
Azficel-T	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Azficel-T.	Approved, Investigational
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ketoprofen.	Approved, Investigational
Azosemide	The therapeutic efficacy of Azosemide can be decreased when used in combination with Ketoprofen.	Investigational
Balsalazide	Ketoprofen may increase the nephrotoxic activities of Balsalazide.	Approved, Investigational
Becaplermin	Ketoprofen may increase the anticoagulant activities of Becaplermin.	Approved, Investigational
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Beclomethasone dipropionate.	Approved, Investigational
Befunolol	Ketoprofen may decrease the antihypertensive activities of Befunolol.	Experimental
Bekanamycin	Ketoprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.	Experimental
Benazepril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Benazepril.	Approved, Investigational
Bendazac	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bendazac.	Experimental
Bendroflumethiazide	The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ketoprofen.	Approved
Benorilate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Benorilate.	Experimental
Benoxaprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Benoxaprofen.	Withdrawn
Benzydamine	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Benzydamine.	Approved
Beraprost	The therapeutic efficacy of Beraprost can be decreased when used in combination with Ketoprofen.	Investigational
Betamethasone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Betamethasone.	Approved, Vet Approved
Betaxolol	Ketoprofen may decrease the antihypertensive activities of Betaxolol.	Approved, Investigational
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Ketoprofen.	Approved, Investigational
Bevantolol	Ketoprofen may decrease the antihypertensive activities of Bevantolol.	Approved
Bevonium	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bevonium.	Experimental
Bimatoprost	The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ketoprofen.	Approved, Investigational
Bisoprolol	Ketoprofen may decrease the antihypertensive activities of Bisoprolol.	Approved
Bivalirudin	Ketoprofen may increase the anticoagulant activities of Bivalirudin.	Approved, Investigational
Bopindolol	Ketoprofen may decrease the antihypertensive activities of Bopindolol.	Approved
Bromfenac	The risk or severity of adverse effects can be increased when Bromfenac is combined with Ketoprofen.	Approved
Bucillamine	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bucillamine.	Investigational
Bucindolol	Ketoprofen may decrease the antihypertensive activities of Bucindolol.	Investigational
Budesonide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Budesonide.	Approved
Bufexamac	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bufexamac.	Approved, Experimental
Bufuralol	Ketoprofen may decrease the antihypertensive activities of Bufuralol.	Experimental, Investigational
Bumadizone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bumadizone.	Experimental
Bumetanide	The therapeutic efficacy of Bumetanide can be decreased when used in combination with Ketoprofen.	Approved
Bupranolol	Ketoprofen may decrease the antihypertensive activities of Bupranolol.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Ketoprofen.	Experimental
Candesartan cilexetil	The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Ketoprofen.	Approved
Candoxatril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Candoxatril.	Experimental
Capecitabine	The metabolism of Ketoprofen can be decreased when combined with Capecitabine.	Approved, Investigational
Captopril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Captopril.	Approved
Carbamazepine	The metabolism of Ketoprofen can be increased when combined with Carbamazepine.	Approved, Investigational
Carbaspirin calcium	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Carbaspirin calcium.	Experimental, Investigational
Carboprost Tromethamine	The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ketoprofen.	Approved
Carprofen	The risk or severity of adverse effects can be increased when Carprofen is combined with Ketoprofen.	Approved, Vet Approved, Withdrawn
Carteolol	Ketoprofen may decrease the antihypertensive activities of Carteolol.	Approved
Carvedilol	Ketoprofen may decrease the antihypertensive activities of Carvedilol.	Approved, Investigational
Castanospermine	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Castanospermine.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Celecoxib.	Approved, Investigational
Celiprolol	Ketoprofen may decrease the antihypertensive activities of Celiprolol.	Approved, Investigational
Ceritinib	The serum concentration of Ketoprofen can be increased when it is combined with Ceritinib.	Approved
Certoparin	Ketoprofen may increase the anticoagulant activities of Certoparin.	Approved, Investigational
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with Ketoprofen.	Approved, Investigational, Vet Approved
Chlorothiazide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketoprofen.	Approved, Vet Approved
Chlorthalidone	The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ketoprofen.	Approved
Cholecalciferol	The metabolism of Ketoprofen can be decreased when combined with Cholecalciferol.	Approved, Nutraceutical
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Choline magnesium trisalicylate.	Approved
Ciclesonide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ciclesonide.	Approved, Investigational
Cilazapril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Cilazapril.	Approved
Cinoxacin	Ketoprofen may increase the neuroexcitatory activities of Cinoxacin.	Approved, Investigational, Withdrawn
Citric Acid	Ketoprofen may increase the anticoagulant activities of Citric Acid.	Approved, Nutraceutical, Vet Approved
Clobetasol	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clobetasol.	Approved, Investigational
Clobetasol propionate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clobetasol propionate.	Approved
Clobetasone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clobetasone.	Approved
Clocortolone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clocortolone.	Approved
Clodronic Acid	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clodronic Acid.	Approved, Investigational, Vet Approved
Clonixin	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clonixin.	Approved
Cloprostenol	The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Ketoprofen.	Vet Approved
Cloranolol	Ketoprofen may decrease the antihypertensive activities of Cloranolol.	Experimental
Clotrimazole	The metabolism of Ketoprofen can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Colesevelam	Colesevelam can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Cortexolone 17α-propionate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Cortexolone 17α-propionate.	Investigational
Corticosterone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Corticosterone.	Experimental
Cortisone acetate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Cortisone acetate.	Approved, Investigational
Crisaborole	The metabolism of Ketoprofen can be decreased when combined with Crisaborole.	Approved, Investigational
Curcumin	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Curcumin.	Approved, Investigational
Cyclopenthiazide	The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Ketoprofen.	Experimental
Cyclosporine	Ketoprofen may increase the nephrotoxic activities of Cyclosporine.	Approved, Investigational, Vet Approved
Dabigatran etexilate	Ketoprofen may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Dabrafenib	The serum concentration of Ketoprofen can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Dalteparin	Ketoprofen may increase the anticoagulant activities of Dalteparin.	Approved
Danaparoid	Ketoprofen may increase the anticoagulant activities of Danaparoid.	Approved, Withdrawn
Darexaban	Ketoprofen may increase the anticoagulant activities of Darexaban.	Investigational
Daunorubicin	Ketoprofen may decrease the excretion rate of Daunorubicin which could result in a higher serum level.	Approved
Deferasirox	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Deferasirox.	Approved, Investigational
Deflazacort	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Deflazacort.	Approved, Investigational
Delapril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Delapril.	Experimental
Delavirdine	The metabolism of Ketoprofen can be decreased when combined with Delavirdine.	Approved
Desirudin	Ketoprofen may increase the anticoagulant activities of Desirudin.	Approved
Desmopressin	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desmopressin.	Approved
Desonide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desonide.	Approved, Investigational
Desoximetasone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoximetasone.	Approved
Desoxycorticosterone acetate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoxycorticosterone acetate.	Approved
Desoxycorticosterone Pivalate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoxycorticosterone Pivalate.	Experimental, Vet Approved
Dexamethasone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Dexamethasone isonicotinate.	Vet Approved
Dexketoprofen	The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Ketoprofen.	Approved, Investigational
Dextran	Ketoprofen may increase the anticoagulant activities of Dextran.	Approved, Investigational, Vet Approved
Dextran 40	Ketoprofen may increase the anticoagulant activities of Dextran 40.	Approved
Dextran 70	Ketoprofen may increase the anticoagulant activities of Dextran 70.	Approved
Dextran 75	Ketoprofen may increase the anticoagulant activities of Dextran 75.	Approved
Dibekacin	Ketoprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level.	Experimental
Dibotermin alfa	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Dibotermin alfa.	Approved, Investigational
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Ketoprofen.	Approved, Vet Approved
Dicoumarol	Ketoprofen may increase the anticoagulant activities of Dicoumarol.	Approved
Difenpiramide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Difenpiramide.	Experimental
Diflorasone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Diflorasone.	Approved
Diflunisal	The risk or severity of adverse effects can be increased when Diflunisal is combined with Ketoprofen.	Approved, Investigational
Difluocortolone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Difluocortolone.	Approved, Investigational, Withdrawn
Difluprednate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Difluprednate.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Ketoprofen.	Approved
Dihydrostreptomycin	Ketoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.	Investigational, Vet Approved
Dinoprost	The therapeutic efficacy of Dinoprost can be decreased when used in combination with Ketoprofen.	Investigational
Dinoprost Tromethamine	The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Ketoprofen.	Approved, Vet Approved
Dinoprostone	The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Ketoprofen.	Approved
Dosulepin	The metabolism of Ketoprofen can be decreased when combined with Dosulepin.	Approved
Doxorubicin	Ketoprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.	Approved, Investigational
Drospirenone	Ketoprofen may increase the hyperkalemic activities of Drospirenone.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Droxicam.	Withdrawn
Duvelisib	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Duvelisib.	Investigational
E-6201	The risk or severity of adverse effects can be increased when Ketoprofen is combined with E-6201.	Investigational
Edetic Acid	Ketoprofen may increase the anticoagulant activities of Edetic Acid.	Approved, Vet Approved
Edoxaban	Ketoprofen may increase the anticoagulant activities of Edoxaban.	Approved
Efavirenz	The metabolism of Ketoprofen can be decreased when combined with Efavirenz.	Approved, Investigational
Enalapril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Enalapril.	Approved, Vet Approved
Enalaprilat	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Enalaprilat.	Approved
Enoxacin	Ketoprofen may increase the neuroexcitatory activities of Enoxacin.	Approved, Investigational
Enoxaparin	Ketoprofen may increase the anticoagulant activities of Enoxaparin.	Approved
Enprostil	The therapeutic efficacy of Enprostil can be decreased when used in combination with Ketoprofen.	Experimental
Epanolol	Ketoprofen may decrease the antihypertensive activities of Epanolol.	Experimental
Epirizole	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Epirizole.	Approved
Epirubicin	Ketoprofen may decrease the excretion rate of Epirubicin which could result in a higher serum level.	Approved
Epitizide	The therapeutic efficacy of Epitizide can be decreased when used in combination with Ketoprofen.	Experimental
Eplerenone	Ketoprofen may decrease the antihypertensive activities of Eplerenone.	Approved
Epoprostenol	The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ketoprofen.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Ketoprofen.	Approved
Equilenin	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Equilenin.	Experimental
Equilin	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Equilin.	Approved
Esmolol	Ketoprofen may decrease the antihypertensive activities of Esmolol.	Approved
Estrone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Estrone.	Approved
Estrone sulfate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Estrone sulfate.	Approved
Etacrynic acid	The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ketoprofen.	Approved, Investigational
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Ketoprofen.	Approved, Investigational
Ethenzamide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ethenzamide.	Experimental
Ethyl biscoumacetate	Ketoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Etidronic acid	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Etidronic acid.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Etodolac.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Etofenamate.	Approved, Investigational
Etoricoxib	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Etoricoxib.	Approved, Investigational
Etravirine	The metabolism of Ketoprofen can be decreased when combined with Etravirine.	Approved
Evening primrose oil	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Evening primrose oil.	Approved, Investigational
Exisulind	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Exisulind.	Investigational
Felbinac	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Felbinac.	Experimental
Fenbufen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fenbufen.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fenoprofen is combined with Ketoprofen.	Approved
Fenprostalene	The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Ketoprofen.	Vet Approved
Fentiazac	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fentiazac.	Experimental
Feprazone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Feprazone.	Experimental
Ferulic acid	Ketoprofen may increase the anticoagulant activities of Ferulic acid.	Experimental
Fimasartan	The risk or severity of adverse effects can be increased when Fimasartan is combined with Ketoprofen.	Approved, Investigational
Fleroxacin	Ketoprofen may increase the neuroexcitatory activities of Fleroxacin.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Ketoprofen.	Approved, Withdrawn
Floxuridine	The metabolism of Ketoprofen can be decreased when combined with Floxuridine.	Approved
Fluasterone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluasterone.	Investigational
Fluconazole	The metabolism of Ketoprofen can be decreased when combined with Fluconazole.	Approved, Investigational
Fludrocortisone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fludrocortisone.	Approved, Investigational
Fluindione	Ketoprofen may increase the anticoagulant activities of Fluindione.	Approved, Investigational
Flumequine	Ketoprofen may increase the neuroexcitatory activities of Flumequine.	Withdrawn
Flumethasone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Flumethasone.	Approved, Vet Approved
Flunisolide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Flunisolide.	Approved, Investigational
Flunixin	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Flunixin.	Vet Approved
Flunoxaprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Flunoxaprofen.	Experimental
Fluocinolone Acetonide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocinolone Acetonide.	Approved, Investigational, Vet Approved
Fluocinonide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocinonide.	Approved, Investigational
Fluocortolone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocortolone.	Approved, Withdrawn
Fluorometholone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluorometholone.	Approved, Investigational
Fluorouracil	The metabolism of Ketoprofen can be decreased when combined with Fluorouracil.	Approved
Fluprednidene	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluprednidene.	Approved, Withdrawn
Fluprednisolone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluprednisolone.	Approved
Fluprostenol	The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Ketoprofen.	Vet Approved
Flurandrenolide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Flurandrenolide.	Approved
Flurbiprofen	The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ketoprofen.	Approved, Investigational
Fluticasone furoate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluticasone furoate.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluticasone propionate.	Approved
Fluvastatin	The metabolism of Ketoprofen can be decreased when combined with Fluvastatin.	Approved
Fluvoxamine	The metabolism of Ketoprofen can be decreased when combined with Fluvoxamine.	Approved, Investigational
Folic Acid	The therapeutic efficacy of Folic Acid can be decreased when used in combination with Ketoprofen.	Approved, Nutraceutical, Vet Approved
Fondaparinux	Ketoprofen may increase the anticoagulant activities of Fondaparinux.	Approved, Investigational
Fondaparinux sodium	Ketoprofen may increase the anticoagulant activities of Fondaparinux sodium.	Approved, Investigational
Forasartan	The risk or severity of adverse effects can be increased when Forasartan is combined with Ketoprofen.	Experimental
Formestane	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Formestane.	Approved, Investigational, Withdrawn
Fosinopril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fosinopril.	Approved
Fosphenytoin	The metabolism of Ketoprofen can be increased when combined with Fosphenytoin.	Approved, Investigational
Framycetin	Ketoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.	Approved
Furosemide	The therapeutic efficacy of Furosemide can be decreased when used in combination with Ketoprofen.	Approved, Vet Approved
Gabexate	Ketoprofen may increase the anticoagulant activities of Gabexate.	Investigational
Garenoxacin	Ketoprofen may increase the neuroexcitatory activities of Garenoxacin.	Investigational
Gatifloxacin	Ketoprofen may increase the neuroexcitatory activities of Gatifloxacin.	Approved, Investigational
Gemeprost	The therapeutic efficacy of Gemeprost can be decreased when used in combination with Ketoprofen.	Approved, Withdrawn
Gemfibrozil	The metabolism of Ketoprofen can be decreased when combined with Gemfibrozil.	Approved
Gemifloxacin	Ketoprofen may increase the neuroexcitatory activities of Gemifloxacin.	Approved, Investigational
Geneticin	Ketoprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.	Experimental
Gentamicin	Ketoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.	Approved, Vet Approved
GENTAMICIN C1A	Ketoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.	Experimental
GPX-150	Ketoprofen may decrease the excretion rate of GPX-150 which could result in a higher serum level.	Investigational
Grepafloxacin	Ketoprofen may increase the neuroexcitatory activities of Grepafloxacin.	Approved, Investigational, Withdrawn
Guacetisal	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Guacetisal.	Experimental
Halcinonide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Halcinonide.	Approved, Investigational, Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Haloperidol.	Approved
HE3286	The risk or severity of adverse effects can be increased when Ketoprofen is combined with HE3286.	Investigational
Heparin	Ketoprofen may increase the anticoagulant activities of Heparin.	Approved, Investigational
Higenamine	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Higenamine.	Investigational
Hydralazine	Ketoprofen may decrease the antihypertensive activities of Hydralazine.	Approved
Hydrochlorothiazide	The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ketoprofen.	Approved, Vet Approved
Hydrocortisone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Hydrocortisone.	Approved, Vet Approved
Hydroflumethiazide	The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ketoprofen.	Approved, Investigational
Hygromycin B	Ketoprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.	Vet Approved
Ibandronate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibandronate.	Approved, Investigational
Ibuprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibuprofen.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibuproxam.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Icatibant.	Approved, Investigational
Idarubicin	Ketoprofen may decrease the excretion rate of Idarubicin which could result in a higher serum level.	Approved
Idraparinux	Ketoprofen may increase the anticoagulant activities of Idraparinux.	Investigational
Iloprost	The therapeutic efficacy of Iloprost can be decreased when used in combination with Ketoprofen.	Approved, Investigational
Imidapril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Imidapril.	Investigational
Imidazole salicylate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Imidazole salicylate.	Experimental
Indapamide	The therapeutic efficacy of Indapamide can be decreased when used in combination with Ketoprofen.	Approved
Indenolol	Ketoprofen may decrease the antihypertensive activities of Indenolol.	Withdrawn
Indinavir	The metabolism of Ketoprofen can be decreased when combined with Indinavir.	Approved
Indobufen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Indobufen.	Investigational
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Ketoprofen.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Indoprofen.	Withdrawn
Irbesartan	The metabolism of Ketoprofen can be decreased when combined with Irbesartan.	Approved, Investigational
Isepamicin	Ketoprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level.	Experimental
Isoxicam	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Isoxicam.	Withdrawn
Istaroxime	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Istaroxime.	Investigational
Kanamycin	Ketoprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.	Approved, Investigational, Vet Approved
Kebuzone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Kebuzone.	Experimental
Ketoconazole	The metabolism of Ketoprofen can be decreased when combined with Ketoconazole.	Approved, Investigational
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Ketoprofen.	Approved
Labetalol	Ketoprofen may decrease the antihypertensive activities of Labetalol.	Approved
Landiolol	Ketoprofen may decrease the antihypertensive activities of Landiolol.	Investigational
Latanoprost	The therapeutic efficacy of Latanoprost can be decreased when used in combination with Ketoprofen.	Approved, Investigational
Latanoprostene Bunod	The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Ketoprofen.	Approved, Investigational
Leflunomide	The metabolism of Ketoprofen can be decreased when combined with Leflunomide.	Approved, Investigational
Lepirudin	Ketoprofen may increase the anticoagulant activities of Lepirudin.	Approved
Letaxaban	Ketoprofen may increase the anticoagulant activities of Letaxaban.	Investigational
Levobunolol	Ketoprofen may decrease the antihypertensive activities of Levobunolol.	Approved
Levofloxacin	Ketoprofen may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Limaprost	The therapeutic efficacy of Limaprost can be decreased when used in combination with Ketoprofen.	Approved, Investigational
Lisinopril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Lisinopril.	Approved, Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Lisofylline.	Investigational
Lithium	The serum concentration of Lithium can be increased when it is combined with Ketoprofen.	Approved
Lobeglitazone	The metabolism of Ketoprofen can be decreased when combined with Lobeglitazone.	Approved, Investigational
Lonazolac	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Lonazolac.	Experimental
Lornoxicam	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Lornoxicam.	Approved, Investigational
Losartan	The metabolism of Ketoprofen can be decreased when combined with Losartan.	Approved
Loteprednol	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Loteprednol.	Approved
Lovastatin	The metabolism of Ketoprofen can be decreased when combined with Lovastatin.	Approved, Investigational
Loxoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Loxoprofen.	Approved, Investigational
Lubiprostone	The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ketoprofen.	Approved, Investigational
Lumacaftor	The serum concentration of Ketoprofen can be decreased when it is combined with Lumacaftor.	Approved
Lumiracoxib	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Lumiracoxib.	Approved, Investigational
Luprostiol	The therapeutic efficacy of Luprostiol can be decreased when used in combination with Ketoprofen.	Vet Approved
Magnesium salicylate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Magnesium salicylate.	Approved
Manidipine	The metabolism of Ketoprofen can be decreased when combined with Manidipine.	Approved, Investigational
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Ketoprofen.	Approved, Investigational
ME-609	The risk or severity of adverse effects can be increased when Ketoprofen is combined with ME-609.	Investigational
Meclofenamic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ketoprofen.	Approved, Vet Approved
Medrysone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Medrysone.	Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ketoprofen.	Approved
Melagatran	Ketoprofen may increase the anticoagulant activities of Melagatran.	Experimental
Melengestrol	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Melengestrol.	Vet Approved
Meloxicam	The risk or severity of adverse effects can be increased when Meloxicam is combined with Ketoprofen.	Approved, Vet Approved
Mepindolol	Ketoprofen may decrease the antihypertensive activities of Mepindolol.	Experimental
Mesalazine	Ketoprofen may increase the nephrotoxic activities of Mesalazine.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Metamizole.	Approved, Investigational, Withdrawn
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Ketoprofen.	Approved
Methyclothiazide	The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketoprofen.	Approved
Methylprednisolone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Methylprednisolone.	Approved, Vet Approved
Metipranolol	Ketoprofen may decrease the antihypertensive activities of Metipranolol.	Approved
Metolazone	The therapeutic efficacy of Metolazone can be decreased when used in combination with Ketoprofen.	Approved
Metoprolol	Ketoprofen may decrease the antihypertensive activities of Metoprolol.	Approved, Investigational
Metrizamide	Ketoprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.	Approved
Micronomicin	Ketoprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level.	Experimental
Midostaurin	The metabolism of Ketoprofen can be decreased when combined with Midostaurin.	Approved, Investigational
Mifamurtide	The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Ketoprofen.	Approved, Experimental
Mifepristone	The serum concentration of Ketoprofen can be increased when it is combined with Mifepristone.	Approved, Investigational
Misoprostol	The therapeutic efficacy of Misoprostol can be decreased when used in combination with Ketoprofen.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Mizoribine.	Investigational
Moexipril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Moexipril.	Approved
Mofebutazone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Mofebutazone.	Experimental
Mometasone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Mometasone.	Approved, Vet Approved
Morniflumate	The risk or severity of adverse effects can be increased when Morniflumate is combined with Ketoprofen.	Approved
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ketoprofen.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Mycophenolic acid.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Nabumetone.	Approved
Nadolol	Ketoprofen may decrease the antihypertensive activities of Nadolol.	Approved
Nadroparin	Ketoprofen may increase the anticoagulant activities of Nadroparin.	Approved, Investigational
Nafamostat	Ketoprofen may increase the anticoagulant activities of Nafamostat.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Ketoprofen.	Approved
Nalidixic Acid	Ketoprofen may increase the neuroexcitatory activities of Nalidixic Acid.	Approved, Investigational
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Ketoprofen.	Approved, Vet Approved
NCX 1022	The risk or severity of adverse effects can be increased when Ketoprofen is combined with NCX 1022.	Investigational
Neamine	Ketoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.	Experimental
Nebivolol	Ketoprofen may decrease the antihypertensive activities of Nebivolol.	Approved, Investigational
Nemonoxacin	Ketoprofen may increase the neuroexcitatory activities of Nemonoxacin.	Investigational
Neomycin	Ketoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.	Approved, Vet Approved
Nepafenac	The risk or severity of adverse effects can be increased when Nepafenac is combined with Ketoprofen.	Approved, Investigational
Netilmicin	Ketoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.	Approved, Investigational
Nicardipine	The metabolism of Ketoprofen can be decreased when combined with Nicardipine.	Approved, Investigational
Nifenazone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Nifenazone.	Experimental
Niflumic Acid	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Niflumic Acid.	Approved
Nimesulide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Nimesulide.	Approved, Investigational, Withdrawn
Nitroaspirin	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Nitroaspirin.	Investigational
Norfloxacin	Ketoprofen may increase the neuroexcitatory activities of Norfloxacin.	Approved
Oleoyl-estrone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Oleoyl-estrone.	Investigational
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Ketoprofen.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Ketoprofen.	Approved
Olsalazine	Ketoprofen may increase the nephrotoxic activities of Olsalazine.	Approved
Omacetaxine mepesuccinate	The risk or severity of bleeding can be increased when Ketoprofen is combined with Omacetaxine mepesuccinate.	Approved, Investigational
Omapatrilat	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Omapatrilat.	Investigational
Omeprazole	The metabolism of Ketoprofen can be decreased when combined with Omeprazole.	Approved, Investigational, Vet Approved
Orgotein	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Orgotein.	Vet Approved
Otamixaban	Ketoprofen may increase the anticoagulant activities of Otamixaban.	Investigational
Oxaprozin	The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ketoprofen.	Approved
Oxolinic acid	Ketoprofen may increase the neuroexcitatory activities of Oxolinic acid.	Experimental
Oxprenolol	Ketoprofen may decrease the antihypertensive activities of Oxprenolol.	Approved
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Oxyphenbutazone.	Approved, Withdrawn
Pamidronate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pamidronate.	Approved
Paramethasone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Paramethasone.	Approved
Parecoxib	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Parecoxib.	Approved
Paromomycin	Ketoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.	Approved, Investigational
Parthenolide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Parthenolide.	Approved, Investigational
Pazufloxacin	Ketoprofen may increase the neuroexcitatory activities of Pazufloxacin.	Investigational
Pefloxacin	Ketoprofen may increase the neuroexcitatory activities of Pefloxacin.	Approved
Penbutolol	Ketoprofen may decrease the antihypertensive activities of Penbutolol.	Approved, Investigational
Pentaerythritol Tetranitrate	Ketoprofen may increase the anticoagulant activities of Pentaerythritol Tetranitrate.	Approved
Pentosan Polysulfate	Ketoprofen may increase the anticoagulant activities of Pentosan Polysulfate.	Approved
Perindopril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Perindopril.	Approved
Phenindione	Ketoprofen may increase the anticoagulant activities of Phenindione.	Approved, Investigational
Phenobarbital	The metabolism of Ketoprofen can be increased when combined with Phenobarbital.	Approved, Investigational
Phenprocoumon	Ketoprofen may increase the anticoagulant activities of Phenprocoumon.	Approved, Investigational
Phenylbutazone	The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ketoprofen.	Approved, Vet Approved
Phenytoin	The metabolism of Ketoprofen can be increased when combined with Phenytoin.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ketoprofen.	Approved, Investigational
Pindolol	Ketoprofen may decrease the antihypertensive activities of Pindolol.	Approved, Investigational
Pipemidic acid	Ketoprofen may increase the neuroexcitatory activities of Pipemidic acid.	Experimental
Pirarubicin	Ketoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.	Investigational
Piretanide	The therapeutic efficacy of Piretanide can be decreased when used in combination with Ketoprofen.	Approved
Pirfenidone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pirfenidone.	Approved, Investigational
Piromidic acid	Ketoprofen may increase the neuroexcitatory activities of Piromidic acid.	Experimental
Piroxicam	The risk or severity of adverse effects can be increased when Piroxicam is combined with Ketoprofen.	Approved, Investigational
Pirprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pirprofen.	Experimental
Pitolisant	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pitolisant.	Approved, Investigational
Platelet Activating Factor	Ketoprofen may decrease the antihypertensive activities of Platelet Activating Factor.	Experimental
Plazomicin	Ketoprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level.	Investigational
Plicamycin	Ketoprofen may decrease the excretion rate of Plicamycin which could result in a higher serum level.	Approved, Investigational, Withdrawn
Polythiazide	The therapeutic efficacy of Polythiazide can be decreased when used in combination with Ketoprofen.	Approved
Practolol	Ketoprofen may decrease the antihypertensive activities of Practolol.	Approved
Pralatrexate	The serum concentration of Pralatrexate can be increased when it is combined with Ketoprofen.	Approved, Investigational
Pranoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pranoprofen.	Experimental, Investigational
Prasterone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Prasterone.	Approved, Investigational, Nutraceutical
Prasterone sulfate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Prasterone sulfate.	Investigational
Prednicarbate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednicarbate.	Approved, Investigational
Prednisolone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednisolone.	Approved, Vet Approved
Prednisone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednisone.	Approved, Vet Approved
Pregnenolone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pregnenolone.	Approved, Experimental, Investigational
Primidone	The metabolism of Ketoprofen can be increased when combined with Primidone.	Approved, Vet Approved
Probenecid	The serum concentration of Ketoprofen can be increased when it is combined with Probenecid.	Approved, Investigational
Proglumetacin	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Proglumetacin.	Experimental
Propacetamol	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Propacetamol.	Approved, Investigational
Propranolol	Ketoprofen may decrease the antihypertensive activities of Propranolol.	Approved, Investigational
Propyphenazone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Propyphenazone.	Experimental
Proquazone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Proquazone.	Experimental
Prostaglandin B2	The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Ketoprofen.	Experimental
Prostaglandin G2	The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Ketoprofen.	Experimental
Prostalene	The therapeutic efficacy of Prostalene can be decreased when used in combination with Ketoprofen.	Vet Approved
Protein C	Ketoprofen may increase the anticoagulant activities of Protein C.	Approved
Protein S human	Ketoprofen may increase the anticoagulant activities of Protein S human.	Approved
Protocatechualdehyde	Ketoprofen may increase the anticoagulant activities of Protocatechualdehyde.	Approved
Prulifloxacin	Ketoprofen may increase the neuroexcitatory activities of Prulifloxacin.	Investigational
PTC299	The risk or severity of adverse effects can be increased when Ketoprofen is combined with PTC299.	Investigational
Puromycin	Ketoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.	Experimental
Pyrimethamine	The metabolism of Ketoprofen can be decreased when combined with Pyrimethamine.	Approved, Investigational, Vet Approved
Quinapril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Quinapril.	Approved, Investigational
Quinethazone	The therapeutic efficacy of Quinethazone can be decreased when used in combination with Ketoprofen.	Approved
Quinine	The metabolism of Ketoprofen can be decreased when combined with Quinine.	Approved
Ramipril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ramipril.	Approved
Rescinnamine	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Rescinnamine.	Approved
Resveratrol	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Resveratrol.	Approved, Experimental, Investigational
Reviparin	Ketoprofen may increase the anticoagulant activities of Reviparin.	Approved, Investigational
Ribostamycin	Ketoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.	Approved, Investigational
Rifampicin	The metabolism of Ketoprofen can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Ketoprofen can be increased when combined with Rifapentine.	Approved, Investigational
Rimexolone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Rimexolone.	Approved
Risedronate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Risedronate.	Approved, Investigational
Rivaroxaban	Ketoprofen may increase the anticoagulant activities of Rivaroxaban.	Approved
Rofecoxib	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Rofecoxib.	Approved, Investigational, Withdrawn
Rosoxacin	Ketoprofen may increase the neuroexcitatory activities of Rosoxacin.	Approved, Investigational
Rucaparib	The metabolism of Ketoprofen can be decreased when combined with Rucaparib.	Approved, Investigational
Rufloxacin	Ketoprofen may increase the neuroexcitatory activities of Rufloxacin.	Experimental
Sabarubicin	Ketoprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level.	Investigational
Sacubitril	The risk or severity of adverse effects can be increased when Sacubitril is combined with Ketoprofen.	Approved
Salicylamide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Salicylamide.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Ketoprofen.	Approved, Investigational, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Salsalate.	Approved
Saprisartan	The risk or severity of adverse effects can be increased when Saprisartan is combined with Ketoprofen.	Experimental
Saralasin	The risk or severity of adverse effects can be increased when Saralasin is combined with Ketoprofen.	Investigational
Sarilumab	Sarilumab may increase the immunosuppressive activities of Ketoprofen.	Approved, Investigational
Secobarbital	The metabolism of Ketoprofen can be increased when combined with Secobarbital.	Approved, Vet Approved
Semapimod	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Semapimod.	Investigational
Seratrodast	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Seratrodast.	Approved
Serrapeptase	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Serrapeptase.	Investigational
Sildenafil	The metabolism of Ketoprofen can be decreased when combined with Sildenafil.	Approved, Investigational
Sisomicin	Ketoprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.	Investigational
Sitafloxacin	Ketoprofen may increase the neuroexcitatory activities of Sitafloxacin.	Experimental, Investigational
Sodium phosphate	Sodium phosphate may increase the nephrotoxic activities of Ketoprofen.	Approved
Sorafenib	The metabolism of Ketoprofen can be decreased when combined with Sorafenib.	Approved, Investigational
Sotalol	Ketoprofen may decrease the antihypertensive activities of Sotalol.	Approved
SP1049C	Ketoprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.	Investigational
Sparfloxacin	Ketoprofen may increase the neuroexcitatory activities of Sparfloxacin.	Approved, Investigational
Spectinomycin	Ketoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.	Approved, Investigational, Vet Approved
Spirapril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Spirapril.	Approved
Spironolactone	Ketoprofen may decrease the antihypertensive activities of Spironolactone.	Approved
SRT501	The risk or severity of adverse effects can be increased when Ketoprofen is combined with SRT501.	Investigational
Streptomycin	Ketoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.	Approved, Vet Approved
Streptozocin	Ketoprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.	Approved, Investigational
Sulfadiazine	The metabolism of Ketoprofen can be decreased when combined with Sulfadiazine.	Approved, Investigational, Vet Approved
Sulfamethoxazole	The metabolism of Ketoprofen can be decreased when combined with Sulfamethoxazole.	Approved
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ketoprofen.	Approved
Sulfisoxazole	The metabolism of Ketoprofen can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Ketoprofen.	Approved, Investigational
Sulodexide	Ketoprofen may increase the anticoagulant activities of Sulodexide.	Approved, Investigational
Sulprostone	The therapeutic efficacy of Sulprostone can be decreased when used in combination with Ketoprofen.	Investigational
Suprofen	The risk or severity of adverse effects can be increased when Suprofen is combined with Ketoprofen.	Approved, Withdrawn
Suxibuzone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Suxibuzone.	Experimental
Tacrolimus	Ketoprofen may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Tafluprost	The therapeutic efficacy of Tafluprost can be decreased when used in combination with Ketoprofen.	Approved
Talinolol	Ketoprofen may decrease the antihypertensive activities of Talinolol.	Investigational
Talniflumate	The risk or severity of adverse effects can be increased when Talniflumate is combined with Ketoprofen.	Approved
Tarenflurbil	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tarenflurbil.	Investigational
Tasosartan	The risk or severity of adverse effects can be increased when Tasosartan is combined with Ketoprofen.	Approved
Technetium Tc-99m etidronate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Technetium Tc-99m etidronate.	Approved
Technetium Tc-99m medronate	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Technetium Tc-99m medronate.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Ketoprofen.	Approved, Investigational
Temafloxacin	Ketoprofen may increase the neuroexcitatory activities of Temafloxacin.	Withdrawn
Temocapril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Temocapril.	Experimental, Investigational
Tenidap	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tenidap.	Experimental
Tenofovir disoproxil	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tenofovir disoproxil.	Approved, Investigational
Tenoxicam	The risk or severity of adverse effects can be increased when Tenoxicam is combined with Ketoprofen.	Approved
Tepoxalin	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tepoxalin.	Vet Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Teriflunomide.	Approved
Tertatolol	Ketoprofen may decrease the antihypertensive activities of Tertatolol.	Experimental
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tiaprofenic acid.	Approved
Ticagrelor	The metabolism of Ketoprofen can be decreased when combined with Ticagrelor.	Approved
Ticlopidine	The metabolism of Ketoprofen can be decreased when combined with Ticlopidine.	Approved
Tiludronic acid	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tiludronic acid.	Approved, Investigational, Vet Approved
Timolol	Ketoprofen may decrease the antihypertensive activities of Timolol.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tinoridine.	Investigational
Tixocortol	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tixocortol.	Approved, Withdrawn
Tobramycin	Ketoprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.	Approved, Investigational
Tolbutamide	The metabolism of Ketoprofen can be decreased when combined with Tolbutamide.	Approved, Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tolfenamic Acid.	Approved, Investigational
Tolmetin	The risk or severity of adverse effects can be increased when Tolmetin is combined with Ketoprofen.	Approved
Topiroxostat	The metabolism of Ketoprofen can be decreased when combined with Topiroxostat.	Approved, Investigational
Torasemide	The therapeutic efficacy of Torasemide can be decreased when used in combination with Ketoprofen.	Approved
Trandolapril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Trandolapril.	Approved
Tranilast	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tranilast.	Approved, Investigational
Travoprost	The therapeutic efficacy of Travoprost can be decreased when used in combination with Ketoprofen.	Approved
Treprostinil	The risk or severity of adverse effects can be increased when Treprostinil is combined with Ketoprofen.	Approved, Investigational
Triamcinolone	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Triamcinolone.	Approved, Vet Approved
Triamterene	Ketoprofen may decrease the antihypertensive activities of Triamterene.	Approved
Tribenoside	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tribenoside.	Experimental
Trichlormethiazide	The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ketoprofen.	Approved, Vet Approved
Trimethoprim	The metabolism of Ketoprofen can be decreased when combined with Trimethoprim.	Approved, Vet Approved
Triptolide	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Triptolide.	Investigational
Trovafloxacin	Ketoprofen may increase the neuroexcitatory activities of Trovafloxacin.	Approved, Investigational, Withdrawn
Troxerutin	Ketoprofen may increase the anticoagulant activities of Troxerutin.	Investigational
Ulobetasol	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ulobetasol.	Approved
Unoprostone	The therapeutic efficacy of Unoprostone can be decreased when used in combination with Ketoprofen.	Approved, Investigational
Valdecoxib	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Valdecoxib.	Approved, Investigational, Withdrawn
Valproic Acid	The metabolism of Ketoprofen can be decreased when combined with Valproic Acid.	Approved, Investigational
Valrubicin	Ketoprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.	Approved
Valsartan	The metabolism of Ketoprofen can be decreased when combined with Valsartan.	Approved, Investigational
Vancomycin	The serum concentration of Vancomycin can be increased when it is combined with Ketoprofen.	Approved
Voriconazole	The metabolism of Ketoprofen can be decreased when combined with Voriconazole.	Approved, Investigational
Warfarin	Ketoprofen may increase the anticoagulant activities of Warfarin.	Approved
Ximelagatran	Ketoprofen may increase the anticoagulant activities of Ximelagatran.	Approved, Investigational, Withdrawn
Zafirlukast	The metabolism of Ketoprofen can be decreased when combined with Zafirlukast.	Approved, Investigational
Zaltoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Zaltoprofen.	Approved, Investigational
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Ketoprofen.	Approved, Investigational, Withdrawn
Zofenopril	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Zofenopril.	Experimental
Zoledronic acid	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Zoledronic acid.	Approved
Zomepirac	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Zomepirac.	Withdrawn
Zoptarelin doxorubicin	Ketoprofen may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.	Investigational
Zorubicin	Ketoprofen may decrease the excretion rate of Zorubicin which could result in a higher serum level.	Experimental

Food Interactions

• Avoid alcohol.
• Food prolongs rate of absorption and decreases peak plasma concentration. Extent of absorption is not affected.
• Take with food to reduce gastric irritation.

References

Synthesis Reference

Attilio Citterio, Daniele Fancelli, "Method of preparing ketoprofen." U.S. Patent US4845281, issued December, 1982.

US4845281

General References

1. Kantor TG: Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy. 1986 May-Jun;6(3):93-103. [PubMed:3526298]
2. Mazieres B: Topical ketoprofen patch. Drugs R D. 2005;6(6):337-44. [PubMed:16274258]

External Links

Human Metabolome Database

HMDB0015144

KEGG Drug

D00132

KEGG Compound

C01716

PubChem Compound

3825

PubChem Substance

46505715

ChemSpider

3693

BindingDB

50022271

ChEBI

6128

ChEMBL

CHEMBL571

Therapeutic Targets Database

DAP000623

PharmGKB

PA450149

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

PDRhealth

PDRhealth Drug Page

Wikipedia

Ketoprofen

ATC Codes

M01AE53 — Ketoprofen, combinations

• M01AE — Propionic acid derivatives
• M01A — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
• M01 — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
• M — MUSCULO-SKELETAL SYSTEM

M02AA10 — Ketoprofen

• M02AA — Antiinflammatory preparations, non-steroids for topical use
• M02A — TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
• M02 — TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
• M — MUSCULO-SKELETAL SYSTEM

M01AE03 — Ketoprofen

• M01AE — Propionic acid derivatives
• M01A — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
• M01 — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
• M — MUSCULO-SKELETAL SYSTEM

AHFS Codes

• 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents

FDA label

Download (160 KB)

MSDS

Download (75.9 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Treatment	Painful musculoskeletal conditions	1
1	Recruiting	Treatment	Renal Colic	1
2	Completed	Not Available	Knee Osteoarthritis (Knee OA)	1
2	Completed	Treatment	Knee Osteoarthritis (Knee OA)	1
2	Completed	Treatment	Tendonitis of the Shoulder, Elbow, or Knee	1
2	Recruiting	Treatment	Neoplasms, Upper Aerodigestive Tract / Uterine Cervical Cancer	1
2	Unknown Status	Treatment	Post-Operative Pain / Surgery, Cardiac	1
2, 3	Completed	Treatment	Female Genital Diseases	1
3	Completed	Not Available	Ankle Sprains	1
3	Completed	Prevention	Migraines	1
3	Completed	Prevention	Pain Relief	2
3	Completed	Treatment	Acute Soft Tissue Injury / Muscle Strain / Sprains	1
3	Completed	Treatment	Ankle Sprains	1
3	Completed	Treatment	Bursitis / Tendonitis	1
3	Completed	Treatment	Knee Osteoarthritis (Knee OA)	1
3	Completed	Treatment	Low Back Pain (LBP)	1
3	Completed	Treatment	Muscle Strain / Sprains	1
3	Completed	Treatment	Osteoarthritis (OA)	1
3	Completed	Treatment	Pain	3
3	Not Yet Recruiting	Treatment	Painful musculoskeletal conditions	2
3	Recruiting	Treatment	Prophylaxis against postoperative nausea and vomiting	1
3	Terminated	Treatment	Bursitis / Tendonitis	1
3	Unknown Status	Treatment	Muscular Atrophy / Sprains / Tendonitis	1
3	Withdrawn	Treatment	Acute Pain (Flare) Associated With Osteoarthritis (OA) of the Knee	1
3	Withdrawn	Treatment	Migraines	1
3	Withdrawn	Treatment	Sprains	1
4	Completed	Supportive Care	Other Surgical Procedures / Pain	1
4	Completed	Treatment	Ankle Sprains	1
4	Completed	Treatment	Caesarian Section	1
4	Completed	Treatment	Children / Postoperative pain / Recovery of Function	1
4	Completed	Treatment	General Surgery	1
4	Completed	Treatment	Gonarthrosis / Low Back Pain (LBP)	1
4	Completed	Treatment	Pain	1
4	Completed	Treatment	Sciatica	1
4	Not Yet Recruiting	Treatment	Cesarean Section / Pain, Neuropathic / Postoperative pain	1
4	Not Yet Recruiting	Treatment	Cesarean Section / Postoperative pain	1
4	Recruiting	Treatment	Ankle Sprains	1
4	Recruiting	Treatment	Cesarean Section / Pain Management / Pain, Neuropathic	1
4	Recruiting	Treatment	Mechanical Low Back Pain	1
4	Suspended	Treatment	Acute Renal Colic / Renal Colic	1
4	Terminated	Treatment	Analgesia, Postoperative	1
4	Terminated	Treatment	Pharyngotonsillitis	1
Not Available	Completed	Diagnostic	Dermatitis, Photocontact	1
Not Available	Completed	Treatment	Migraines	1
Not Available	Completed	Treatment	Pregnancy Termination	1

Pharmacoeconomics

Manufacturers

• Elan pharmaceutical research corp
• Mylan pharmaceuticals inc
• Watson laboratories inc florida
• Wyeth pharmaceuticals inc
• Heritage pharmaceuticals inc
• Sandoz inc
• Teva pharmaceuticals usa inc
• Wyeth ayerst laboratories
• Novartis consumer health inc
• Bayer healthcare llc
• L perrigo co
• Wyeth consumer healthcare

Packagers

• Aidarex Pharmacuticals LLC
• Apothecary Shop Wholesale
• A-S Medication Solutions LLC
• Bryant Ranch Prepack
• Corepharma LLC
• Direct Dispensing Inc.
• Dispensing Solutions
• Diversified Healthcare Services Inc.
• Elan Pharmaceuticals Inc.
• H.J. Harkins Co. Inc.
• Innoviant Pharmacy Inc.
• Letco Medical Inc.
• Major Pharmaceuticals
• Medisca Inc.
• Murfreesboro Pharmaceutical Nursing Supply
• Mylan
• Nucare Pharmaceuticals Inc.
• Palmetto Pharmaceuticals Inc.
• PD-Rx Pharmaceuticals Inc.
• Pharma Pac LLC
• Pharmedix
• Physicians Total Care Inc.
• Preferred Pharmaceuticals Inc.
• Prescription Dispensing Service Inc.
• Professional Co.
• Qualitest
• Rebel Distributors Corp.
• Sandhills Packaging Inc.
• Southwood Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Watson Pharmaceuticals

Dosage forms

Form	Route	Strength
Capsule	Oral	50 mg
Capsule	Oral	50 mg/1
Capsule	Oral	75 mg/1
Capsule, extended release	Oral	200 mg/1
Tablet	Oral	75 mg/1
Tablet, extended release	Oral	200 mg
Tablet, delayed release	Oral	100 mg
Tablet, delayed release	Oral	50 mg
Suppository	Rectal	50 mg
Capsule, extended release	Oral	150 mg
Capsule, extended release	Oral	200 mg
Suppository	Rectal	100 mg
Kit

Prices

Unit description	Cost	Unit
Ketoprofen powder	43.74USD	g
Ketoprofen micronized powder	3.84USD	g
Ketoprofen CR 200 mg 24 Hour Capsule	2.8USD	capsule
Orudis 75 mg capsule	1.58USD	capsule
Apo-Keto Sr 200 mg Sustained-Release Tablet	1.46USD	tablet
Ketoprofen 75 mg capsule	1.12USD	capsule
Pms-Ketoprofen 100 mg Suppository	1.1USD	suppository
Ketoprofen 50 mg capsule	1.0USD	capsule
Apo-Keto-E 100 mg Enteric-Coated Tablet	0.71USD	tablet
Apo-Keto 50 mg Capsule	0.35USD	capsule
Apo-Keto-E 50 mg Enteric-Coated Tablet	0.35USD	tablet
Orudis kt 12.5 mg tablet	0.3USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	94 °C	U.S. Patent 3,641,127.
water solubility	51 mg/L (at 22 °C)	YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP	3.12	SANGSTER (1993)
logS	-3.7	ADME Research, USCD
pKa	4.45	SANGSTER (1994)

Predicted Properties

Property	Value	Source
Water Solubility	0.0213 mg/mL	ALOGPS
logP	3.29	ALOGPS
logP	3.61	ChemAxon
logS	-4.1	ALOGPS
pKa (Strongest Acidic)	3.88	ChemAxon
pKa (Strongest Basic)	-7.5	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	54.37 Å2	ChemAxon
Rotatable Bond Count	4	ChemAxon
Refractivity	72.52 m3·mol-1	ChemAxon
Polarizability	26.56 Å3	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9928
Blood Brain Barrier	+	0.9382
Caco-2 permeable	+	0.8866
P-glycoprotein substrate	Non-substrate	0.7132
P-glycoprotein inhibitor I	Non-inhibitor	0.9168
P-glycoprotein inhibitor II	Non-inhibitor	0.9589
Renal organic cation transporter	Non-inhibitor	0.8818
CYP450 2C9 substrate	Non-substrate	0.7183
CYP450 2D6 substrate	Non-substrate	0.9598
CYP450 3A4 substrate	Non-substrate	0.7685
CYP450 1A2 substrate	Non-inhibitor	0.9046
CYP450 2C9 inhibitor	Non-inhibitor	0.907
CYP450 2D6 inhibitor	Non-inhibitor	0.9604
CYP450 2C19 inhibitor	Non-inhibitor	0.9465
CYP450 3A4 inhibitor	Non-inhibitor	0.9598
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9438
Ames test	Non AMES toxic	0.9801
Carcinogenicity	Non-carcinogens	0.6299
Biodegradation	Ready biodegradable	0.6701
Rat acute toxicity	2.2378 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9661
hERG inhibition (predictor II)	Non-inhibitor	0.9595

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-0a4i-0390000000-a31eea165d399e00a838
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-0002-0900000000-520a79bdaf7ce3ec476c
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-0002-0900000000-3aa1f85f9b6550cc9147
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-0002-0900000000-d582a4bd39cf003e73e3
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-0002-0900000000-5a1b8d289986b0103991
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-0a4i-0390000000-66208a90d621bcbafe58
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-0002-0900000000-e3e8663a70e4a78219d3
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-0a4i-0090000000-adc690db13d79d7e088b
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-0a4i-0090000000-dc927e8f8991af0b9c62
LC-MS/MS Spectrum - LC-ESI-QTOF , negative	LC-MS/MS	splash10-0a4i-0090000000-2f4539685044ce030904
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-0002-0900000000-ef4640dd80e9b12e93de
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-0a4i-0090000000-c153f6a533277453ee05
LC-MS/MS Spectrum - LC-ESI-ITFT , negative	LC-MS/MS	splash10-0a4i-0090000000-b4720ed0a7abab74acb0
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0a4i-0090000000-e4776b39ad9777a106d6
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0a4i-0190000000-cd73850fa213100eea4f
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0a6u-0940000000-b2b661b497cc37bb54d7
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0090000000-60f88de41010fba22c8b
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0090000000-8b462ef2178ab7ffdf4f
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0290000000-a6f4442004890a1099fa
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0960000000-ea2a1b4ccfd466afd1d7
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0900000000-ffa78d310365a0a9dd0e
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-2900000000-3f15ff6dad9be8084701
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a6r-5900000000-0e2bf00920a7e1627e89
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0090000000-4894675edf8eca790257
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0290000000-c4ff029474813952fb93
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0960000000-fd0fa1645957bec680d0
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0900000000-1eb5023e779f64d2c54c
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-2900000000-e94235cda691beca3668
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a6r-5900000000-e7c564751c1ab453ec7d
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0090000000-3c2483071b054192073e
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0910000000-03f114a8dcdd26a59b2c
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a6r-3900000000-456c7673c9f0423e5676
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0090000000-bfc6ecc839166fb81ec4
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0090000000-9feded821a3159f1a9be
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0a4i-0690000000-96f041a385b1f0080005
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0a4i-0910000000-ad714bb911021f04971b
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0pb9-0900000000-0c0d84c0eaff25680e89
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0a4i-0490000000-39b45e31d0deb851ba88
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0a4i-2490000000-437617eb0a03874b42b5
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0a4i-3910000000-f7e3f020e942509b83e3
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0a4i-0890000000-abbc4b713cf8dac1afc9

Taxonomy

Description

This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Benzophenones

Direct Parent

Benzophenones

Alternative Parents

Diphenylmethanes / Aryl-phenylketones / Phenylpropanoic acids / Benzoyl derivatives / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives

Substituents

Benzophenone / Aryl-phenylketone / Diphenylmethane / 2-phenylpropanoic-acid / Benzoyl / Aryl ketone / Ketone / Carboxylic acid derivative / Carboxylic acid / Monocarboxylic acid or derivatives

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

benzophenones, oxo monocarboxylic acid (CHEBI:6128)

Drug created on June 13, 2005 07:24 / Updated on April 17, 2018 01:03